MARKET

CELG-RT

CELG-RT

Bristol-Myers Squibb Company Celegne Contingent Value Rights
NYSE
0.0640
-0.0009
-1.39%
Closed 09:30 02/28 EST
OPEN
0.0640
PREV CLOSE
0.0649
HIGH
0.0640
LOW
0.0640
VOLUME
100
TURNOVER
0
52 WEEK HIGH
0.1500
52 WEEK LOW
0.0192
MARKET CAP
45.53M
P/E (TTM)
0.0080
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CELG RT last week (0219-0223)?
Weekly Report · 2d ago
Weekly Report: what happened at CELG RT last week (0212-0216)?
Weekly Report · 02/19 09:17
Weekly Report: what happened at CELG RT last week (0205-0209)?
Weekly Report · 02/12 09:15
Weekly Report: what happened at CELG RT last week (0129-0202)?
Weekly Report · 02/05 09:16
Weekly Report: what happened at CELG RT last week (0122-0126)?
Weekly Report · 01/29 09:15
Weekly Report: what happened at CELG RT last week (0115-0119)?
Weekly Report · 01/22 09:16
Weekly Report: what happened at CELG RT last week (0108-0112)?
Weekly Report · 01/15 09:16
Weekly Report: what happened at CELG RT last week (0101-0105)?
Weekly Report · 01/08 09:16
More
About CELG-RT
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Webull offers Celgene Corporation stock information, including NYSE: CELG RT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CELG RT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CELG-RT stock methods without spending real money on the virtual paper trading platform.